NKMAX said on Thursday that it has received FDA approval for its natural killer (NK) cell therapy SNK01 to treat Parkinson's disease under the Expanded Access Program (EAP). NKMAX has received sympathetic approval from the FDA for its NK cell therapy, SNK01, to treat Parkinson's disease ...